Durable Disease Control After Neoadjuvant Cemiplimab in Resectable Cutaneous Squamous Cell Carcinoma
Final follow-up from a multicenter phase II study has strengthened the case for cemiplimab before surgery in resectable stage II to IV cutaneous squamous cell carcinoma. After a median follow-up of 54 months, investigators observed durable event-free survival, no late recurrence events, and no new safety concerns beyond the original treatment experience. For a tumor type that can behave aggressively when it extends beyond the skin and into regional structures, the long tail of disease control carries clear clinical weight.
The trial enrolled patients with resectable stage II to IV disease and previously established a pathologic complete response rate of 51%. At 19 months, estimated 12-month event-free survival had reached 89%, with 11 events. The final analysis deepens that picture rather than changing it. Across the full follow-up period, 16 event-free survival events occurred, and none represented new disease recurrence. Five of those later events were comorbidity-related deaths without cutaneous squamous cell carcinoma recurrence, a reminder that the survival curve in this population is shaped by both cancer biology and competing medical risk.
A single standout detail carries major practical consequence: among 40 patients with pathologic complete response, none experienced recurrence.
Pathologic Response Tracks with Long-Term Outcome
The final survival estimates line up tightly with the depth of tumor clearance at surgery. Overall estimated 54-month event-free survival was 76.2%, but the response strata separated sharply. Patients with pathologic complete response had an estimated 54-month event-free survival of 81.5%. Those with major pathologic response reached 88.9%, and patients with partial pathologic response reached 100%. By contrast, nonresponders and patients who were not evaluable had an estimated 54-month event-free survival of 45.7%.
Those gradients matter because they suggest the immune response induced before surgery is not merely a short-term cytoreductive effect. In cutaneous squamous cell carcinoma, durable local and systemic control likely depends on eliminating microscopic residual disease at the primary site and in draining lymphatic pathways before those clones establish a foothold. Cemiplimab, by blocking PD-1 signaling, can reinvigorate antitumor T-cell activity at a stage when the tumor burden is still surgically addressable. The data here fit that mechanism: deeper pathologic response corresponded to better long-term freedom from recurrence or death.
The final overall survival estimate at 54 months was 79.4%. In a disease often managed with multimodality therapy, that number cannot be interpreted in isolation, but it does indicate sustained survival in a cohort with advanced localized disease. The absence of new recurrence events in the final analysis is especially notable because late relapses after apparently successful neoadjuvant treatment would have raised concern that early pathologic response might not translate into lasting disease control. No such late signal emerged.
No Late Recurrences and No New Grade 3 Toxicity Signal
Safety remained steady over extended follow-up. No new grade 3 or higher treatment-emergent adverse events occurred in the final analysis. For clinicians weighing neoadjuvant immunotherapy in older patients or in patients already carrying substantial comorbidity, that finding is consequential. The treatment did not generate a delayed toxicity burden that surfaced only after surgery and recovery, and it did not introduce a late adverse-event pattern that would complicate postoperative surveillance.
The trial’s final readout also sharpens the distinction between cancer-related and non-cancer-related outcomes. The five new event-free survival events were comorbidity-related deaths without recurrence of cutaneous squamous cell carcinoma. In practical terms, this means the immune strategy appears to have controlled the malignancy in many patients well enough that the dominant competing hazard became underlying medical illness rather than tumor return. That pattern should influence how multidisciplinary teams counsel patients: neoadjuvant cemiplimab may reduce recurrence risk, but it does not erase the cardiovascular, pulmonary, and frailty-related risks that often define prognosis in an older surgical population.
What the Final Analysis Says About Neoadjuvant Immunotherapy
This study adds to the rationale for moving immunotherapy earlier in the treatment course, before extensive surgery or radiotherapy has altered tissue planes and before microscopic disease has had time to seed new sites. A neoadjuvant PD-1 approach also offers a biologic advantage beyond simple tumor shrinkage: it exposes the intact tumor antigen repertoire to the immune system while the primary lesion is still present, potentially promoting a broader systemic immune response than adjuvant therapy alone. The long-term follow-up seen here is consistent with that premise.
For surgeons, medical oncologists, and dermatologic oncologists, the main message is direct. When cemiplimab produced deep pathologic responses, the benefit was not fleeting. It extended through years of follow-up without late recurrences among patients achieving pathologic complete response and without any new severe toxicity signal emerging over time. The 54-month data therefore support the durability of the neoadjuvant strategy in resectable stage II to IV disease.
The study still leaves important boundaries around patient selection, however. The strongest outcomes clustered in those with pathologic response, while nonresponders and unevaluable patients did much worse. That gap reinforces the need to identify who is most likely to benefit from neoadjuvant PD-1 blockade before treatment begins, since the strategy’s value appears to depend heavily on whether the tumor is immunologically susceptible. Without that information, clinicians may still face the uncomfortable reality of exposing some patients to therapy without achieving the pathologic depth that predicts long-term control.
Even so, this final analysis closes with a clear clinical signal: in resectable cutaneous squamous cell carcinoma, neoadjuvant cemiplimab produced durable event-free survival, preserved overall survival, and no new late safety concerns over 54 months of follow-up.